Logo_AIHTA
  • Deutsch
  • Contact
    • Imprint
      • Privacy Notice
        • Newsletter
          • Sitemap
            Menu_button
            • News
              • About us
                • Research areas
                  • Research Projects
                    • Publications
                      • Search
                        • Announcements
                          • Events
                            • Newsletter
                              • Press release on our reports
                                • Press photos
                                  Video
                                  Video: What is HTA?    
                                  • Home
                                  • News
                                  • Announcements

                                  Announcements

                                  Fotoleiste-1b

                                   

                                  Current & archive

                                  Fotolia-42931175-m1

                                  Carbon ion beam radiotherapy (CIRT) for cancer treatment: a systematic review of effectiveness and safety for 12 oncologic indications.

                                  The project aimed at elaborating possible cancer types, being an indication for carbon ion radiotherapy (CIRT). As such, clinical studies, analysing the use of CIRT for specific cancer types, were identified through a systematic literature search and were reviewed and reported in this project.

                                  Furthermore, a systematic review on the effectiveness (mortality, morbidity) and safety of CIRT for 54 oncologic indications in 12 regions (i.e., skull base, eye, brain, ear-nose-throat, lung, gastrointestinal, bone and soft tissue, prostate, breast, kidney, nervous system, hematologic cancer) was conducted.

                                  Publication: LBI-HTA Project report No. 101: https://eprints.aihta.at/1174/

                                  Contact: Gregor Goetz

                                  More...

                                  2415

                                  Evaluation of individual medical procedures 2018 - Reports

                                  We are pleased to introduce our new reports.

                                  Decison Support Documents 2018

                                  • DSD 109: Subcutaneous implantable cardioverter defibrillator (ICD)
                                    https://eprints.aihta.at/1169
                                  • DSD 110: Lymphovenous anastomoses in patients with primary and secondary lymphoedema
                                    https://eprints.aihta.at/1170
                                  • DSD 111: Allogeneic mesenchymal stem cells for Crohn’s disease-associated complex perianal fistulas
                                    https://eprints.aihta.at/1171
                                  • DSD 112: Meniscal allograft transplantation for post-meniscectomy syndrome
                                    https://eprints.aihta.at/1172
                                  • DSD 113: Baroreceptor activation therapy for treatment-resistant hypertension
                                    https://eprints.aihta.at/1173

                                  + 3 Updates

                                  • DSD 20/4. Update 2018: Endobronchial valve implantation for emphysema
                                    https://eprints.aihta.at/1166
                                  • DSD 37/1. Update 2018: High-intensity focused ultrasound for the treatment of prostate cancer
                                    https://eprints.aihta.at/1167
                                  • DSD 44/3. Update 2018: (Percutaneous) left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation
                                    https://eprints.aihta.at/1168

                                  More...

                                  Fotolia-110033217-s1

                                  Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localized prostate cancer

                                  Irreversible electroporation (IRE, NanoKnife®) is a type of focal therapy which has been suggested as an alternative to radical treatment. It typically uses 3 to 5 electrodes which deliver short repetitive electrical pulses to destroy the cancer cells. Stereotactic radiotherapy (stereotactic body radiation therapy or SBRT) is a type of external radiation in which a higher radiation dose is delivered in a reduced number of fractions as is the case with conventional or moderately fractionated radiation therapy. Proton therapy (PT) is a further type of external radiation therapy which uses high doses of ionizing rays directed at the tumour.  There is at present inadequate and insufficient evidence to show that IRE, SBRT and PT have either a positive impact on survival and quality of life or the ability to prevent or delay prostatectomy.

                                  Publication: LBI-HTA Project report No. 107: https://eprints.aihta.at/1165/

                                  Contact: Claudia Wild

                                  More...

                                  2135

                                  Horizon Scanning in Oncology - Reports

                                  We are pleased to introduce our two new HSO reports.

                                  DSD HSO No. 81
                                  Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma

                                  DSD HSO No. 80
                                  Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non–small-cell lung cancer (NSCLC)

                                  More...

                                  B00056221

                                  Options to identify inappropriate use of MRI, Part 3

                                  The intention of the present MRI report, part 3, is to identify methods for the identification of inappropriate care. In addition, relations between MRI of lower extremities and subsequent (surgical) interventions are evaluated.

                                  In total, we were able to identify 8 methodological approaches to detect in-appropriate care. All methods have certain strengths and weaknesses. The analysis of the relations of MRI to subsequent interventions showed that more knee replacements were in OECD in countries with higher MRI utilization rates. Finally, we were able to identify a series of refunding policies that could exert an influence on MRI utilization.

                                  Publication: LBI-HTA Project report No. 80c: https://eprints.aihta.at/1159/

                                  Contact: Robert Emprechtinger

                                  More...

                                  Fotolia-157154933-m1

                                  Echocardiography: Guideline recommendations and options to identify inappropriate use as well as rate of use in Austria.

                                  Aim of the report at hand is to describe the use of echocardiography in Austria and set it into context with the international literature on the appropriateness of echocardiography.

                                  Repeated echocardiographic exams within one year are often related to inappropriate use. Some districts had notable differences in the ratio of over-all exams to repeated exams. With an increase in the number of overall exams there is a tendency for a higher percentage of repeated exams, especially for regions with very high rates of the use of echocardiography. Since the aim is to improve medical care, a discussion with the stakeholders should be conducted.

                                  Publication: LBI-HTA Project report No. 98: https://eprints.aihta.at/1158/

                                  Contact: Robert Emprechtinger

                                  More...

                                  Fotolia-55196684-s1

                                  Dropouts in Psychotherapy

                                  Part I: Predictors, theories and models to explain and recommend courses of action to avoid discontinuation of therapy

                                  Part II: "Overview of Reviews" on dropouts in psychotherapy

                                  The project dealt in two parts with dropouts in psychotherapies. The first part of the report focused on definitions, parameters for describing psychotherapy dropouts and explanatory models. In addition, dropout predictors were identified at a meta-level, which were further empirically recorded in the second report part by an "Overview of systematic reviews". In this context, evidence synthesis (including 14 systematic reviews/meta-analyses) showed that a (young) age of psychotherapy patients and certain mental disorders (such as personality disorders) can represent relevant risk factors for an unplanned termination of psychotherapy. Dropout predictors, which are more likely to be attributed to psychotherapists, are currently only partially researched. With regard to suitable prevention strategies, eight measures were proposed in the report which, among other things, aimed at organisational aspects (e.g. clarification of therapy goals, possibilities and limits of psychotherapy) and interpersonal factors (e.g. strengthening the therapeutic alliance between patient and psychotherapist).

                                  Publication: LBI-HTA Project report No. 100: https://eprints.aihta.at/1157/

                                  Contact: Roman Winkler

                                  More...

                                  2134

                                  Horizon Scanning in Oncology - Reports

                                  We are pleased to introduce our two new HSO reports.

                                  DSD HSO No. 79
                                  Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)

                                  DSD HSO No. 78
                                  Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC)

                                  More...

                                  Fotolia-168399976-s

                                  Screening for fetal trisomies 21, 18 and 13 by non-invasive prenatal testing (NIPT). EUnetHTA report

                                  Since several years, numerous new non-invasive prenatal tests (NIPTs) have been available to identify common chromosomal anomalies. Most NIPTs are available for trisomies 21, 18 and 13 and sex chromosome aneuploidies, but many laboratories have expanded their range of analysis to include other trisomies and common microdeletions. The main advantage of NIPT compared to the conventional screening approach is the ease of implementation and non-invasiveness of the assay, as well as the potential reduction in false-positive [FP] results. An introduction of non-invasive genetic testing has ethical, social and organizational implications that need to be considered.

                                  Publication: LBI-HTA Project report No. 103: https://eprints.aihta.at/1153/

                                  Contact: Claudia Wild

                                  More...

                                  2133

                                  Horizon Scanning in Oncology - Reports

                                  We are pleased to introduce our new HSO report.

                                  DSD HSO No. 77
                                  Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)

                                  More...

                                  « < ... 17 18 19 20 21 ... > »
                                  Displaying results 181 to 190.
                                  • News
                                    • Announcements
                                      • Events
                                        • Newsletter
                                          • Press release on our reports
                                            • Press photos
                                            • About us
                                              • Evaluation
                                                • History
                                                  • Methods
                                                    • Team
                                                      • Shareholder & organization chart
                                                        • Stakeholder involvement
                                                          • Press clippings
                                                          • Research areas
                                                            • Oncology
                                                              • High tech medicine
                                                                • Rehabilitation and occupational therapy
                                                                  • Prevention and screening
                                                                    • Psychological & psychiatric interventions
                                                                      • Health economics
                                                                        • European collaboration
                                                                          • HTA-methods & steering instruments
                                                                            • Complementary medicine
                                                                            • Research Projects
                                                                              • Synopsis of current research projects
                                                                                • Synopsis of completed research projects
                                                                                  • Decision Support Documents for the Austrian Appraisal Board
                                                                                    • HTA-Information Service Rapid Reviews
                                                                                      • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                                                                        • Horizon Scanning of Medicines - Reports and Fact Sheets
                                                                                          • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                                                                            • Evaluation of individual medical procedures - Reports
                                                                                              • All projects in an overview
                                                                                              • Publications
                                                                                                • Repository
                                                                                                  • HTA-Newsletter
                                                                                                    • Annual Reports
                                                                                                    • Search
                                                                                                      Netzwerk
                                                                                                      • Eunethta
                                                                                                      • Ebm
                                                                                                      • Inahta
                                                                                                      • Dexhelpp
                                                                                                      Shareholder
                                                                                                      • Bmfg
                                                                                                      • Sv
                                                                                                      • Wgfond
                                                                                                      • Noe
                                                                                                      • Ooghfond
                                                                                                      • Ghls
                                                                                                      • Tirol
                                                                                                      • Vorarlberg
                                                                                                      • Kghfond
                                                                                                      • Ghpf
                                                                                                      • Burgef
                                                                                                      • Contact
                                                                                                        • Imprint
                                                                                                          • Privacy Notice
                                                                                                            • Newsletter
                                                                                                              • Sitemap
                                                                                                                © 2025 HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Alle Rechte vorbehalten.
                                                                                                                • Log in